AnaptysBio (NASDAQ:ANAB) Announces Earnings Results

AnaptysBio (NASDAQ:ANAB) released its quarterly earnings results on Tuesday. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58, Zacks reports. The company had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

AnaptysBio Trading Up 3.6%

Shares of AnaptysBio stock traded up $1.24 during trading on Wednesday, reaching $35.98. The stock had a trading volume of 212,624 shares, compared to its average volume of 698,844. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.03 and a beta of 0.16. The stock has a fifty day moving average price of $27.75 and a two-hundred day moving average price of $24.37. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $39.78.

Wall Street Analyst Weigh In

ANAB has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. HC Wainwright raised their price target on shares of AnaptysBio from $38.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Wells Fargo & Company lifted their price objective on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays assumed coverage on AnaptysBio in a research report on Monday, October 13th. They issued an “overweight” rating and a $78.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.30.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors have recently bought and sold shares of ANAB. AQR Capital Management LLC grew its stake in shares of AnaptysBio by 153.3% during the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock worth $558,000 after acquiring an additional 18,165 shares in the last quarter. Creative Planning boosted its holdings in AnaptysBio by 26.9% during the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock worth $374,000 after purchasing an additional 3,571 shares during the last quarter. JPMorgan Chase & Co. grew its position in AnaptysBio by 1,631.6% in the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after purchasing an additional 233,325 shares in the last quarter. Russell Investments Group Ltd. bought a new position in AnaptysBio in the second quarter valued at $528,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in AnaptysBio during the 2nd quarter worth about $3,348,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.